Biocryst Pharmaceuticals, Inc.

Pravin L Kotian

Yarlagadda Sudhakara Babu

V Satish Kumar

Weihe Zhang

Minwan Wu

Venkat R Chintareddy

Pooran Chand

Krishnan Raman

Shanta Bantia

Lakshminarayana Vogeti

Peng-Cheng Lu

Yahya El-Kattan

Zhao Dang

Trung Xuan Nguyen

Wei Lv

Tsu-Hsing Lin

Ajit K Ghosh

Shri Niwas

R Scott Rowland

John A Montgomery

William P Sheridan

Scott R Rowland

Yarlagadda S Babu

Satish V Kumar

Satish Kumar V

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

Pyrrolo 12.3-dipyrimidine compounds and analogues thereof

Human plasma kallikrein inhibitors

Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

Imidazole-containing inhibitors of ALK2 kinase

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of viral RNA polymerase. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or suppression of a Zika virus infection or a disease or condition associated with a Zika virus infection.

Methods and compositions for treatment of Zika virus infection

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva. 

Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity. 

Prodrugs of kallikrein inhibitors

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity. 

Growing community of inventors

Hoover, AL, United States of America

Pravin L Kotian